Johnson & Johnson on Tuesday announced a licensing deal with Vedanta Biosciences to develop the privately held company's lead microbiome-based drug candidate for inflammatory bowel disorders, such as Crohn's disease and ulcerative colitis. J&J said Vedanta will receive an undisclosed upfront payment and would be eligible to receive up to $241 million for achieving development and commercial milestones.